Patents
Literature
4 results about "Staphylococcus haemolyticus" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Staphylococcus haemolyticus is a member of the coagulase-negative staphylococci (CoNS). It is part of the skin flora of humans, and its largest populations are usually found at the axillae, perineum, and inguinal areas. S. haemolyticus also colonizes primates and domestic animals. It is a well-known opportunistic pathogen, and is the second-most frequently isolated CoNS (S. epidermidis is the first). Infections can be localized or systemic, and are often associated with the insertion of medical devices. The highly antibiotic-resistant phenotype and ability to form biofilms make S. haemolyticus a difficult pathogen to treat.
Phyllospheric fungus DP16 and application thereof
The invention discloses a strain of phyllosphere fungus (Muyocopron lithocarpi) DP16 and application of the strain of Muyocopron lithocarpi) DP16 and application of the strain of Muyocopron lithocarpi. The strain DP16 provided by the invention is preserved in the China Center for Type Culture Collection on June 23, 2025, and the preservation number is CCTCC NO: M 20251445. The DP16 provided by the invention can be used for effectively inhibiting various plant pathogenic fungi and bacteria, and particularly shows strong activity on elaeagnus pungens, staphylococcus haemolyticus, African neem brown root pathogenic bacteria and the like. And the fermentation extract also has obvious oxidation resistance. The invention further provides an optimal fermentation culture method of the strain, an extraction method of secondary metabolites and application of the strain in preparation of biological control preparations and antioxidants, and important microbial resources and technical support are provided for development of novel and safe biopesticides and functional products.
Owner:SOUTH CHINA AGRICULTURAL UNIVERSITY
Lyophilized formulations of antibacterial proteins
A freeze-dried formulation includes an antibacterial protein having a killing activity specific to at least one or all of the following genera: Staphylococcus arlettae, Staphylococcus aureus, Staphylococcus auricularis, Staphylococcus carnosus, Staphylococcus caprae, Staphylococcus chromogenes, Staphylococcus cohnii, Staphylococcus delphini, Staphylococcus epidermidis, Staphylococcus equorum, Staphylococcus gallinarum, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus intermedius, Staphylococcus kloosii, Staphylococcus lentus, Staphylococcus lugdunensis, Staphylococcus muscae, Staphylococcus pasteuri, Staphylococcus saprophyticus, Staphylococcus warneri, and Staphylococcus xylosus; a poloxamer; a sugar; and an amino acid.
Owner:INTRON BIOTECHNOLOGY INC
Methods and compositions for reducing malodor
PCT designated stageWO2026106950A1Cosmetic preparationsCarbon-sulfur lyasesBiotechnologyStaphylococcus haemolyticus
The present technology relates generally to the field of reducing, preventing, or ameliorating the generation of undesirable body odors emanating from the skin. In particular, the present technology discloses ApatB-Staphylococcus haemolyticus bacterial strains, which have been modified to reduce or prevent the production of 3-methyl-3- sulfanylhexan-l-ol (3M3SH), compositions and pharmaceutical comprising one or more of said strains, methods of genetically engineering said strains, methods for reducing body odor using said strains, and methods for altering a microbiome using said strains.
Owner:TAXA TECHNOLOGIES INC
Bacillus cereus ATP synthase beta subunit antibacterial peptide BaD9 and application thereof
The application discloses a bacillus cereus ATP synthase beta subunit antibacterial peptide BaD9, and the amino acid sequence of the bacillus cereus ATP synthase beta subunit antibacterial peptide BaD9 is KLVVHRARRIQFFLSQNFH, and the molecular weight of the antibacterial peptide is 2396.831 Dalton. The antibacterial peptide has obvious inhibiting effect on Vibrio parahaemolyticus, Staphylococcus aureus and Staphylococcus haemolyticus, and can be used for preparing medicines for preventing or inhibiting Vibrio parahaemolyticus, Staphylococcus aureus and Staphylococcus haemolyticus infection, food preservatives or feed additives.
Owner:JIMEI UNIV